NCT05144087View on ClinicalTrials.gov

The Influence of Mepolizumab on Structural and Inflammatory Cells in Severe Eosinophilic Asthma

Active, not recruitingOBSERVATIONAL
Enrollment

18

Participants

Timeline

Start Date

May 25, 2022

Primary Completion Date

May 30, 2024

Study Completion Date

November 30, 2027

Conditions
Asthma; Eosinophilic
Trial Locations (1)

SO16 6YD

NIHR Clinical Research Facility, Southampton

All Listed Sponsors
collaborator

University of Southampton

OTHER

collaborator

King's College Hospital NHS Trust

OTHER

lead

University Hospital Southampton NHS Foundation Trust

OTHER